At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Jim Routt
Advertisement
Vice President and Unit Head, Oncology Global Therapeutic Delivery, IQVIA
Articles by Jim Routt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial
2
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
3
How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials
4
FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue
5